Teladoc, Inc. (NYSE:TDOC) CFO Mark Hirschhorn sold 25,000 shares of the stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $32.37, for a total value of $809,250.00. Following the sale, the chief financial officer now owns 20,887 shares of the company’s stock, valued at $676,112.19. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Mark Hirschhorn also recently made the following trade(s):

  • On Tuesday, October 17th, Mark Hirschhorn sold 35,000 shares of Teladoc stock. The shares were sold at an average price of $32.84, for a total value of $1,149,400.00.
  • On Monday, October 2nd, Mark Hirschhorn sold 10,000 shares of Teladoc stock. The shares were sold at an average price of $34.04, for a total value of $340,400.00.
  • On Friday, September 22nd, Mark Hirschhorn sold 25,000 shares of Teladoc stock. The shares were sold at an average price of $31.93, for a total value of $798,250.00.

Teladoc, Inc. (NYSE:TDOC) traded up 0.88% during midday trading on Wednesday, reaching $34.30. The company’s stock had a trading volume of 695,102 shares. Teladoc, Inc. has a 12-month low of $14.00 and a 12-month high of $37.55. The firm’s market cap is $1.94 billion. The company’s 50-day moving average is $33.22 and its 200 day moving average is $33.22.

Teladoc (NYSE:TDOC) last released its earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The business had revenue of $44.60 million for the quarter, compared to the consensus estimate of $44.39 million. Teladoc had a negative net margin of 47.75% and a negative return on equity of 19.88%. The company’s quarterly revenue was up 68.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.38) EPS. Equities analysts forecast that Teladoc, Inc. will post ($1.46) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Teladoc, Inc. (TDOC) CFO Sells 25,000 Shares of Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/18/insider-selling-teladoc-inc-tdoc-cfo-sells-25000-shares-of-stock.html.

Several equities research analysts recently weighed in on TDOC shares. TheStreet cut Teladoc from a “c-” rating to a “d” rating in a report on Monday, July 3rd. Zacks Investment Research cut Teladoc from a “hold” rating to a “sell” rating in a report on Monday, July 17th. Cantor Fitzgerald restated a “hold” rating on shares of Teladoc in a report on Monday, August 28th. Piper Jaffray Companies restated a “buy” rating and set a $32.00 target price on shares of Teladoc in a report on Friday, July 14th. Finally, BidaskClub upgraded Teladoc from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $38.00.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC grew its stake in shares of Teladoc by 1.3% during the second quarter. FMR LLC now owns 8,209,737 shares of the health services provider’s stock valued at $284,879,000 after buying an additional 106,500 shares during the last quarter. BlackRock Inc. grew its stake in shares of Teladoc by 42.9% during the second quarter. BlackRock Inc. now owns 3,844,402 shares of the health services provider’s stock valued at $133,400,000 after buying an additional 1,154,852 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Teladoc by 11.5% during the second quarter. Vanguard Group Inc. now owns 3,041,725 shares of the health services provider’s stock valued at $105,547,000 after buying an additional 314,646 shares during the last quarter. Alliancebernstein L.P. grew its stake in shares of Teladoc by 22.2% during the second quarter. Alliancebernstein L.P. now owns 2,793,590 shares of the health services provider’s stock valued at $96,938,000 after buying an additional 507,390 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Teladoc by 65.8% during the second quarter. JPMorgan Chase & Co. now owns 2,663,600 shares of the health services provider’s stock valued at $92,426,000 after buying an additional 1,057,065 shares during the last quarter. 94.41% of the stock is currently owned by hedge funds and other institutional investors.

About Teladoc

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Insider Buying and Selling by Quarter for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.